Boston Scientific Corporation (BSX)
| Market Cap | 108.94B |
| Revenue (ttm) | 14.71B |
| Net Income (ttm) | 1.77B |
| Shares Out | 1.47B |
| EPS (ttm) | 1.19 |
| PE Ratio | 62.27 |
| Forward PE | 31.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,969,376 |
| Open | 72.74 |
| Previous Close | 72.72 |
| Day's Range | 72.74 - 74.15 |
| 52-Week Range | 48.35 - 74.39 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 75.09 (+1.34%) |
| Earnings Date | Apr 24, 2024 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, c... [Read more]
Financial Performance
In 2023, BSX's revenue was $14.24 billion, an increase of 12.29% compared to the previous year's $12.68 billion. Earnings were $1.57 billion, an increase of 144.55%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is $75.09, which is an increase of 1.34% from the latest price.
News
Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors
MARLBOROUGH, Mass. , May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately.
Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation (BSX) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Boston Scientific Corporation (NYSE:BSX)....
Boston Scientific Beats Forecasts, Boosts Outlook on Booming Heart Device Sales
Shares of Boston Scientific (BSX) hit an all-time high Wednesday as the maker of medical equipment reported better-than-anticipated quarterly results and boosted its guidance on demand for its cardiov...
Boston Scientific Stock Rises on More Than Just an Earnings Beat
The medical-device company tops first-quarter sales and profit estimates.
Boston Scientific raises annual profit forecast on strong demand for heart devices
Medical device maker Boston Scientific raised its annual profit forecast on Wednesday as the company banks on resilient demand for its heart devices, with post-pandemic elective surgical procedures pi...
Boston Scientific's stock jumps 2.7% after earnings top estimates
Boston Scientific Corp.'s stock BSX, +1.43% rose 2.7% early Wednesday, after the medical tech company's first-quarter earnings beat analyst estimates. The company had net income of $495 million, or 33...
Boston Scientific Announces Results for First Quarter 2024
MARLBOROUGH, Mass. , April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported...
FDA classifies recall of Boston Scientific device to treat hemorrhaging as 'most serious'
The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's device used to block blood flow during excessive bleeding or hemorrhaging as most serious.
Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module
MARLBOROUGH, Mass. , April 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and trac...
FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal
Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics.
Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results
MARLBOROUGH, Mass. , April 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter...
Axonics Stockholders Approve Merger Agreement with Boston Scientific
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE: BSX). Accord...
US FDA approves Boston Scientific's heart device
Boston Scientific said on Friday the U.S. Food and Drug Administration has approved its device to treat a complication of heart disease.
Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon
First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass. , March 1, 2024 /PRNewswire/ --...
Boston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes
MARLBOROUGH, Mass. , Feb. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V.
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (N...
Should You Pick Boston Scientific Stock After A Solid Q4 And 13% Uptick This Year?
Boston Scientific BSX (NYSE: BSX) reported its Q4 results last month, with revenues and earnings comfortably beating the street estimates. The company reported revenue of $3.7 billion and adjusted ear...
Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes
MARLBOROUGH, Mass. , Feb. 22, 2024 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V.
Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference
MARLBOROUGH, Mass. , Feb. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6, 2024.
Medical-device makers' stocks jump as procedures keep going strong
Shares of Stryker Corp. SYK, +7.67%, Boston Scientific Corp. BSX, +3.50% and other medical-technology companies jumped Wednesday as sustained demand for medical procedures brightened investors' outloo...
Boston Scientific's stock jumps 5.8% after earnings beat and upbeat guidance
Boston Scientific Corp.'s stock BSX, +0.18% jumped 5.8% early Wednesday, after it beat estimates for the fourth quarter and offered upbeat guidance for 2024. The Marlborough, Mass.
Boston Scientific beats quarterly profit estimates on strong demand for heart devices
Medical device maker Boston Scientific beat Wall Street expectations for fourth-quarter profit on Wednesday, helped by strength in its heart devices unit.
FDA approves Boston Scientific's device for heart condition
Boston Scientific said on Wednesday the U.S. Food and Drug Administration has approved the company's device for a type of heart condition.
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
MARLBOROUGH, Mass. , Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported...
Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System
Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system MARLBOROUGH, Mass. , Jan. 31, 2024 /PRNewswire/ -- Boston Scientific...